greeksoup/ stocks
Stocks / United States / TAK / Planned sales

Takeda Pharmaceutical Company Limited planned insider sales

In the twelve months since 26 September 2025 insiders at Takeda Pharmaceutical Company Limited filed 22 Form 144 notices of planned sales, 967,266 shares worth $16.1 million at the time of filing, from 16 sellers. The latest, filed 10 September 2026: Lauren Rusckowski Duprey (chief transformation officer), 34,535 shares worth $634,408, planned for around 10 September 2026 through Interactive Brokers LLC.

FiledSellerRelationshipSharesValuePlanned saleBrokerHow acquiredFiling
10 September 2026Lauren Rusckowski DupreyChief Transformation Officer34,535$634,40810 September 2026Interactive Brokers LLCRestricted Stock Unit Awards - VestedForm 144
2 September 2026Plump Andrew StewartOfficer116,191$2.1 million2 September 2026Fidelity Brokerage Services LLCRSU's and PSU'sForm 144
19 August 2026Plump Andrew StewartOfficer19,651$363,34819 August 2026Fidelity Brokerage Services LLCRSU's and PSU'sForm 144
14 August 2026Nicola GreenwayChief Human Resources Officer12,980$225,72214 August 2026Interactive Brokers LLCRestricted Stock Unit Awards - VestedForm 144
10 August 2026Elaine ShannonPresident, Global Supply & Quality20,363$355,33411 August 2026Interactive Brokers LLCRestricted Stock Unit Awards - VestedForm 144
6 August 2026Nicola GreenwayChief Human Resources Officer34,603$578,5627 August 2026Interactive Brokers LLCEmployee Stock Purchase Plan; Restricted Stock Unit Awards - VestedForm 144
13 July 2026Elaine ShannonPresident, Global Supply & Quality4,319$72,35113 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Nicola GreenwayChief Human Resources Officer7,348$123,07213 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Ramy RiadPresident, Plasma-Derived Therapies Business Unit7,889$132,14913 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Awny FarajallahChief Medical Officer15,188$254,39913 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Rhonda PachecoPresident, US Business Unit and US Country Head18,316$306,78913 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Marcello Pignagnoli AgostiInterim Head, Strategy and Portfolio Development24,887$416,85013 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Gabriele RicciChief Data & Technology Officer27,197$455,54513 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Natalie FurneyGlobal General Counsel33,454$560,35113 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Giles PlatfordPresident, International Business Unit33,696$564,40613 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Lauren Rusckowski DupreyChief Transformation Officer51,579$863,94713 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Teresa BitettiPresident, Global Oncology Business Unit54,210$908,01913 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Julie KimPresident and CEO96,558$1.6 million13 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
13 July 2026Andrew PlumpPresident, Research & Development179,239$3.0 million13 July 2026Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
9 December 2025Lauren Rusckowski DupreyChief Human Resources Officer29,619$421,1829 December 2025Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
5 December 2025Teresa Marie BitettiPresident, Global Oncology Business Unit87,023$1.2 million5 December 2025Interactive Brokers LLCRestricted Stock Unit Awards - Vested.Form 144
4 December 2025Giles Richard PlatfordPresident, Plasma-Derived Therapies Business Unit58,421$836,0054 December 2025Interactive Brokers LLCRestricted Stock Unit Awards - VestedForm 144

A Form 144 is the notice an insider files with the SEC before selling restricted or control shares over the Rule 144 thresholds; it says what may be sold, not what was. Value is the filer's own aggregate market value. Whether the sale happened shows up later on Form 4, on the insiders page.

Source

Form 144 filings on EDGAR for Takeda Pharmaceutical Company Limited: the company's filing index, each notice read from its own XML.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install